Investors
A MESSAGE FROM OUR CEO
”We are very grateful to those helping with the ADVANCE trial and to all of our shareholders who continue to give us their support.”
-
March 17, 2025 Non RegulatoryThe European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)
-
March 4, 2025 Non RegulatoryPivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
-
February 20, 2025 RegulatorySynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
The interim report for Q4 2024 was published on February 18, 2025, at 07.30 CEST.